Actinium Pharmaceuticals (ATNM) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for November 27, 2024, at The Garden City Hotel, NY, with advance registration required for in-person attendance.

• Stockholders will vote on the election of two Class II directors and the ratification of the independent auditor for 2024.

• Voting can be done in person, by mail, telephone, or Internet, with detailed instructions provided.

• Board recommends voting “FOR” both proposals on the agenda.

Voting matters and shareholder proposals

• Proposal 1: Elect Sandesh Seth and Jeffrey W. Chell as Class II directors for a three-year term expiring at the 2027 Annual Meeting.

• Proposal 2: Ratify Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.

• Board unanimously recommends a vote “FOR” both proposals.

• Stockholders may submit proposals for the 2025 Annual Meeting by July 8, 2025, for inclusion in proxy materials.

Board of directors and corporate governance

• Board consists of six directors divided into three classes, with staggered three-year terms.

• Five directors are considered independent under NYSE American rules.

• Board leadership includes a combined Chairman/CEO and a Lead Independent Director.

• Three standing committees: Audit, Compensation, and Nominating and Corporate Governance, each with independent chairs.

• Board diversity and composition reviewed in 2024, resulting in the addition of Dr. June Almenoff as a director.

• Code of Business Conduct and Ethics applies to all directors, officers, and employees.